electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache

About this update from Electrocore, Inc.

[{"type":"text","content":"ROCKAWAY, NJ, May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore SapphireTM non-invasive vagus nerve stimulation (nVNS) for the treatment of post-traumatic headache (PTH). PTH accounts for approximately 4% of all symptomatic headache disorders1 and is one of the most common consequences of mild traumatic brain injury (mTBI),2,3 also known as concussion. Estimates suggest that 69 million people per year experience a traumatic brain injury (TBI) worldwide.4 In addition, patients with PTH commonly suffer from comorbidities such as anxiety and depression,5 both of which are among the leading causes of disability worldwide.6 The study (GAP-PTH) is a randomized, multi-center, double-blind, parallel, sham-controlled trial enrolling up to 100 veterans and directed by the Veterans Health Administration’s Headache Center of Excellence (HCoE) at the West Haven VA Medical Center in West Haven, CT. PTH is a critical area of concern for the VA and it is estimated that more than 350,000 service members have headaches resulting from TBIs sustained in combat. PTH in veterans is most often caused by the kind of TBIs experienced during combat, including blast wave injuries “PTH is one of the most common presentations among veterans who come to our VA Headache Centers of Excellence around the United States. Last year the Veterans Health Administration was caring for more than 140,000 veterans diagnosed with headache related to head trauma,” commented Dr. Jason Sico, National Director of the VA Headache Centers of Excellence Program and Associate Professor of Neurology (Headache Medicine and Vascular Neurology) and Internal Medicine (General Medicine) Yale School of Medicine. “We have been using gammaCore nVNS successfully in veterans suffering from cluster headache and migraine at our center,” commented Dr. Emmanuelle Schindler, Medical Director of the HCoE at VA Connecticut Healthcare System, Assistant Professor of Neurology at Yale School of Medicine, and primary investigator of the GAP-PTH study. “This will be among the first Randomized Controlled Trials (RCTs) for PTH and we look forward to demonstrating how gammaCore nVNS can help our veterans with PTH....

More updates from Electrocore, Inc.